We use cookies to give you the best online experience. By using our website you agree to our use of cookies in accordance with our cookie policy. Learn more OK
Menu Search : DHCP | LPI - Rheumatology

You are here:

  1. Therapy Areas
  2. DHCP | LPI - Rheumatology
  • Home
  • About Roche
  • Therapy Areas
  • Safety, Health and Wellbeing
  • Media
  • Social Value
  • Careers
  • Contact Us
banner

DHCP | LPI

Rheumatology

Local Prescribing Information (Rheumatology):

 

Tocilizumab Injection IV and SC [Actemra®]

 

 

 

 

Safety Update Information for Healthcare Professionals (Rheumatoid Arthritis):

 

Actemra® (Tocilizumab): A new Important Identified: Hepatotoxicity

 

Share
  • Share via email
  • Share on Facebook
  • Share on Twitter
  • Share on LinkedIn
  • Share on Google+
  • Share on Xing
Close

Related Links

  • Oncology Transplantation Anaemia Rheumatoid Arthritis Haemophilia Personalised Healthcare Cancer Immunotherapy
  • © 2021
  • 07.04.2021
  • Legal Statement
  • Privacy Policy

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin. This website is neither intended nor designed to record or report adverse event information. If you have a suspected side effect or problem to report regarding one of our products, please call the Roche India Safety Unit on +91-98201 63752 or E-mail: [email protected]